BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JL18008 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JL18008\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07579741-1003@assetmemo.bio
DTSTAMP:20261121T005652Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:JL18008: Phase 1/2 readout est. (NCT07579741)
DESCRIPTION:JL18008\, phase 1/2\, HIV.\nStudy: A Study to Evaluate JL18008 
 in Subject With HIV Immunological Non-Responders\nEstimated primary comple
 tion: 12 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/jl18008#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07579741
URL:https://assetmemo.bio/drug/jl18008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443228-1003@assetmemo.bio
DTSTAMP:20261121T005652Z
DTSTART;VALUE=DATE:20291220
DTEND;VALUE=DATE:20291221
SUMMARY:JL18008: Phase 1 readout est. (NCT07443228)
DESCRIPTION:JL18008\, phase 1\, HIV.\nStudy: Recombinant Human Interleukin-
 7 (JL18008) for the Treatment of HIV-Infected Immunological Non-Responders
 \nEstimated primary completion: 20 December 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/jl18008#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07443228
URL:https://assetmemo.bio/drug/jl18008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
